Latest Headlines

  1. Quest Diagnostics To Offer FDA-Cleared Roche pTau217 Blood Test To Assess Alzheimer's Disease Pathology 8/24/2026

    Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced two new developments for its Quest AD-Detect® portfolio of blood-based biomarker tests for Alzheimer's disease, with the goal of broadening access to quality blood tests for evaluating symptomatic patients for Alzheimer's disease.

  2. Purdue Innovation Enhances Multiomics Workflow, Eliminates Sample Preparation 8/24/2026

    A patent-pending method developed and tested for multiple applications at Purdue University eliminates sample preparation, a bottleneck that currently dominates a laboratory scientist’s time and budget, and is amenable with spatial analysis using liquid chromatography-tandem mass spectrometry (LC-MS/MS).

  3. Seek Labs And NAMRU EURAFCENT Enter CRADA To Evaluate Field-Deployable Diagnostics For Infectious Diseases 8/24/2026

    Seek Labs, a private TechBio company building programmable platforms to decode, program, and resolve diseases, today announced a Cooperative Research and Development Agreement (CRADA) with the Naval Medical Research Unit (NAMRU) EURAFCENT, part of Navy Medicine Research & Development that is focused on infectious disease threats affecting military personnel, to evaluate SeekIt™, the company’s instrument-free molecular diagnostic platform. 

  4. Rznomics Joins Lilly Gateway Labs In San Diego To Accelerate RNA Therapeutics 8/23/2026

    Rznomics Inc.(KOSDAQ: 476830), a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced that it is joining Lilly Gateway Labs (LGL) in San Diego, California.

  5. FDA Clears C2N Diagnostics' PrecivityAD2 — First Alzheimer's Blood Test For Adults With Cognitive Symptoms As Young As 40 8/20/2026

    The U.S. Food & Drug Administration (FDA) has cleared C2N Diagnostics’ PrecivityAD2 test, providing patients and health care professionals with an accurate, accessible, and scalable blood test to help diagnose Alzheimer’s disease in conjunction with standard clinical workup.

  6. Pillar Biosciences, LC-SCRUM-Asia And LSI Medience Announce Liquid Biopsy Screening Collaboration In Lung Cancer 8/19/2026

    Pillar Biosciences, Inc. (“Pillar”), LC-SCRUM-Asia and LSI Medience Corporation (“LSI Medience”) today announced a collaboration to support genomic screening of blood-based samples from patients with lung cancer as part of the LC-SCRUM-Asia project in Japan.

  7. 100 U.S. Forensic Labs Are Now Using STRmix 8/19/2026

    One hundred local, state, federal, and private forensic laboratories in the United States are now using STRmix probabilistic genotyping software to resolve mixed DNA profiles previously regarded as too complex or degraded to interpret crime scene evidence.

  8. Cardio Diagnostics Begins In-House Test Processing At Its New High Complexity CLIA-Certified Laboratory In Iowa City 8/18/2026

    Cardio Diagnostics Holdings, Inc., an AI-driven precision cardiovascular medicine company, today announced the official launch of its in-house, high complexity CLIA-certified laboratory in Iowa City, Iowa.

  9. Custom PCR Solutions For Diagnostic Kit Manufacturers 8/18/2026

    Drawing on its trusted 4titude portfolio of PCR products, Azenta Life Sciences has built a reputation of partnering with diagnostic kit manufacturers to develop consumables tailored to their specific workflows.

  10. Century Health And GI Partners Of Illinois Partner To Advance Real-World Evidence In IBD And MASH 8/18/2026

    Century Health, a national leader in AI-powered real-world clinical data and evidence generation, today announced a strategic partnership with GI Partners of Illinois (GIP), the largest independent physician-led gastroenterology practice in Illinois, to build a comprehensive real-world data ecosystem across tens of thousands of patients to advance research in IBD and MASH.